Oncology
4 drugs are in development for Hematologic Malignancies.
- Companies
- 3
- Clinical trials
- 17
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hematologic Malignancies pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| tsc-102-a01 | TScan Therapeutics, Inc. (TCRX) |
Phase 1(2)
| Drug | Company |
|---|---|
| IM-1021 | Immunome Inc. (IMNM) |
| tsc-102-a03 | TScan Therapeutics, Inc. (TCRX) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| sls009 | SELLAS Life Sciences Group, Inc. (SLS) |
About this indication
Hematologic Malignancies context
Oncology·MeSH: Hematologic Neoplasms (D019337)
Also known as: Blood Cancers, Cancer, Blood, Hematologic Malignancy, Hematologic Neoplasm, Hematological Malignancies, Hematological Malignancy, Hematological Neoplasm, Hematological Neoplasms, Neoplasms, Hematologic
Compare drugs
Frequently asked questions
How many drugs are in development for Hematologic Malignancies?
BioSniper tracks 4 drugs in development for Hematologic Malignancies across 3 companies.
How many clinical trials target Hematologic Malignancies?
There are 17 clinical trials targeting Hematologic Malignancies tracked by BioSniper.